July 10, 2025 4:31pm

Although I will reiterate from this a.m.’s post, ““Uncle algo and his electronic trading dwarfs” are hovering, drooling in anticipation and direction”

News: Ultragenyx Pharmaceutical (RARE-10.40 or -25.11% to $31.03) and its partner, London-based Mereo BioPharma Group (MREO -$1.25 or -42.52% to $1.69) rolled out what seemed like a rather ho-hum announcement: Their late-stage trial of a drug called setrusumab, a treatment for the genetic disorder known as brittle bone disease, would continue on as planned. The interim results from the trial missed the statistical bar to end the study. That doesn’t mean the final analysis won’t ultimately show that the drug works. <read more below>

I say what others won’t, so you can do what others can’t!

I also try to answer as many whys, as I can … while providing the metrics to validate my thesis

Never leave an investor uninformed! 

 

My perspective is retail investors should roll-the-dice until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

RegMed Investors’ (RMi) pre-open: Further to run? … https://www.regmedinvestors.com/articles/13991

Wednesday night’s RegMed Investors (RMi) Closing Bell: Riding the wave … https://www.regmedinvestors.com/articles/13990

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed UP +192.34 points or +0.43%, the S&P closed UP +17.20 points or +0.27% while the Nasdaq closed UP +19.33 points or +0.09%

  • Theme of the session, traders shook-off tariff developments as econ (Initial Jobless Claims) fell

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • The number of people who applied for unemployment benefits last week fell to a nearly 2-month low, as a spurt of new jobless claims. Initial jobless claims dropped by 5,000 to 227,000 to in the 7-days ended July 5, based on seasonally adjusted data. The number of jobless workers collecting unemployment benefits rose by 10,000 to 1.97 M, marking the highest level since November 2021.

Thursday’s advance/decline line opened negative with 11 incliners, 21 decliners and 3 flats ending with a positive close of 19 incliners, 14 decliners and 2 flats      

 

Further news review from RARE news title, “We see the market reaction (down 27% after hours) as severely overdone and still believe there is high likelihood that the final analysis in Q4 will be positive, given there will be a longer duration of follow-up and a lower threshold for statistical significance,” William Blair analyst Sami Corwin wrote in a note published early Thursday; rating RAR’s stock at Outperform. < Barron’s>

 

Metrics:  Thursday, the IBB was up +1.36%, the XBI was up +0.51% while the VIX was down -0.18 points or -1.13% at 15.76

 

Q3 – 7/25 – 1 market holiday, 6 positive and 1 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Thursday Closing UP (10 of 19) 

  • Alnylam Pharmaceuticals (ALNY +$1.77 after Wednesday’s +$3.32, Tuesday’s -$6.63 and Monday’s -$7.78),
  • Moderna (MRNA +$1.49),
  • Blueprint Medicine (BPMC +$0.78),
  • Agenus (AGEN +$0.74),
  • Beam Therapeutics (BEAM +$0.57 after Wednesday’s +$1.17, Tuesday’s +$1.11 and Monday’s -$0.83),
  • Mesoblast (MESO +$0.51),
  • BioLife Solutions (BLFS +$0.39 after Wednesday’s -$0.23, Tuesday’s +$0.74 and Monday’s -$1.03),
  • AxoGen (AXGN +$0.29),
  • Adverum Biotechnologies (ADVM +$0.18),
  • Prime Medicine (PRM +$0.15 after Wednesday’s +$0.445),

Flat (2)

  • bluebird bio (BLUE) P/E acquired
  • Homology Medicine (FIXX)

Thursday’s Closing DOWN (10 of 14):

  • Ultragenyx Pharmaceuticals (RARE -$10.40 after Wednesday’s +$2.00 after Tuesday’s -$0.19),
  • CRISPR Therapeutics (CRSP -$1.08 after Wednesday’s +$5.28 after Tuesday’s +$3.62 after Monday’s -$0.980,
  • Lenz Therapeutics (LENZ -$0.56 after Wednesday’s +$3.46 after Tuesday’s -$0.12 after Monday’s -$1.11),
  • Ionis Pharmaceuticals (IONS -$0.45 after Wednesday’s +$1.48 after Tuesday’s -$0.46 after Monday’s -$1.22)
  • Vericel (VCEL -$0.27 after Wednesday’s +$1.26 after Tuesday’s +$0.76 after Monday’s -$2.33),
  • MiMedx (MDXG -$0.18 after Wednesday’s -$0.05, Tuesday’s +$0.52 and Monday’s +$0.15),
  • Regenxbio (RGNX -$0.11),
  • Solid Bioscience (SLDB -$0.10),
  • Verve Therapeutics (VERV -$0.03 after Wednesday’s -$0.02 after Tuesday’s -$0.03),
  • Sangamo Therapeutics (SGMO -$0.0261),

 

The BOTTOM LINE:  Indexes continued their rise on Thursday …

Cell and gene therapy sector equities on Wednesday continued the upside after Tuesday positive close and diving on Monday ….

  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

As I also wrote, the “June Swoon” is over … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

Last session of June as July evolves ‘25: understand the “flow” …

  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats
  • 7/4 – Friday market holiday
  • 7/3 – Thursday closed positive with 23 positive, 6 negative and 6 flats
  • 7/2 - Wednesday closed positive with 24 positive, 7 negative and 4 flats
  • 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Blueprint Medicine (BPMC)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
  • Tuesday: CRISPR Therapeutics (CRSP), Moderna (MRNA) and Beam Therapeutics (BEAM)
  • Monday: Prime Medicine (PRME), AxoGen (AXGN) and MiMedx (MDXG)

The worst three (3) in the session: 

  • Thursday: Ultragenyx Pharmaceuticals (RARE), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
  • Wednesday: BioLife Solutions (BLFS), Harvard Apparatus RT (OTCQB: HRGN) and Brainstorm Cell Therapeutics (BCLI)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Agenus (AGEN)
  • Monday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Lenz Therapeutics (LENZ)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.